CAMP CAMP4 THERAPEUTICS CORPORATION

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences:

Leerink Partners Global Healthcare Conference
Format:Fireside Chat
Date and Time:March 9, 2026, 8:40 a.m. ET
Location:Miami, FL
Webcast Link:
  
Stifel CNS Forum
Format:Corporate Presentation
Date and Time:March 17, 2026, 10:00 a.m. ET
Location:Virtual
Webcast Link:
  
Needham & Company, LLC 25th Annual Healthcare Conference
Format:Corporate Presentation
Date and Time:April 13, 2026, 12:45 p.m. ET
Location:Virtual
Webcast Link:



Live webcasts can be accessed on the investor relations page of CAMP4’s website at . A replay of the webcasts will be archived on the CAMP4 website for 30 days following the presentations.

About CAMP4 Therapeutics

CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.

Contacts

Investor Relations:

Sara Michelmore

Milestone Advisors

Media:

Sofia Bermudez

LifeSci Communications



EN
06/03/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CAMP4 THERAPEUTICS CORPORATION

 PRESS RELEASE

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare ConferenceFormat:Fireside ChatDate and Time:March 9, 2026, 8:40 a.m. ETL...

 PRESS RELEASE

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlight...

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic discoveries, received $17.5 million upfront and eligible for milestone-based payments in addition to tiered royalties Completed private placement with upfront gross proceeds of $50 million, with potential for up to an additional $50 million of gross proceeds, as well as underwritten offering of common...

 PRESS RELEASE

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rul...

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) --  (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on February 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,0...

 PRESS RELEASE

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rul...

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) --  (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,00...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch